Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia

American Journal of Health-System Pharmacy

Volumn 70, Issue 12, 2013, Pages 1025-1032

  Radvansky, Lauren J ^a   Pace, Makala B ^b   Siddiqui, Asif ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c Thoracic Head and Neck Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; MOUTHWASH; PALIFERMIN; PILOCARPINE; SALIVA SUBSTITUTE; TOPICAL AGENT; ANALGESIC AGENT; RADIOPROTECTIVE AGENT;

ADVERSE DRUG REACTION; ANALGESIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DRUG DOSE REGIMEN; EMULSION; HUMAN; MOUTH HYGIENE; ORAL MUCOSITIS; PATIENT CARE; PATIENT EDUCATION; PHARMACIST; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INDUCED ORAL MUCOSITIS; RADIATION INDUCED XEROSTOMIA; RADIATION INJURY; REVIEW; SELF CARE; WOUND DRESSING; XEROSTOMIA; CLINICAL PROTOCOL; COMORBIDITY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEOPLASM; RADIATION RESPONSE; RISK FACTOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AMIFOSTINE; ANALGESICS; ANTINEOPLASTIC PROTOCOLS; COMBINED MODALITY THERAPY; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MUCOSITIS; NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIODERMATITIS; RISK FACTORS; SALIVA, ARTIFICIAL; XEROSTOMIA;

EID: 84886442857     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120467     Document Type: Review

References (52)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
2. American Society for Radiation Oncology. Fast facts about radiation therapy. www.astro.org/News-and-Media/Media-Resources/FAQs/Fast-Facts-About-Radiation-Therapy/Index.aspx (accessed 2012 Apr 30).
3. Halperin EC, Perez CA, Brady LW. The discipline of radiation oncology. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:2-75.
4. Constine LS, Milano MT, Friedman D et al. Late effects of cancer treatment on normal tissues. In: Ibid:320-55.
5. Morgan MA, Ten Haken RK, Lawrence TS. Radiation oncology. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. De-Vita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:289-311.
6. Deng G, Cassileth BR. Supportive care and quality of life. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:2011-20.
7. Smith BD, Haffty BG, Wilson LD et al. The future of radiation oncology in the United States from 2010 to 2020: will supply keep pace with demand? J Clin Oncol. 2010; 28:5160-5.
8. Bureau of Labor Statistics, Department of Labor. Occupational outlook handbook: pharmacists. www.bls.gov/ooh/healthcare/pharmacists.htm (accessed 2012 Apr 30).
9. Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006; 54:28-46.
10. McQuestion M. Evidence-based skin care management in radiation therapy: clinical update. Semin Oncol Nurs. 2011; 27:e1-17.
11. National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.03 (June 14, 2010). http://evs.nci.nih.gov/ftp1/CTCAE/About.html (accessed 2012 May 8).
12. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2008; 19:142-9.
13. Bolderston A, Lloyd NS, Wong RK et al. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006; 14:802-17.
14. Glees JP, Mameghan-Zadeh H, Sparkes CG. Effectiveness of topical steroids in the control of radiation dermatitis: a randomised trial using 1% hydrocortisone cream and 0.05% clobetasone butyrate (Eumovate). Clin Radiol. 1979; 30:397-403.
15. Schmuth M, Wimmer MA, Hofer S et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol. 2002; 146:983-91.
16. Coulomb B, Friteau L, Dubertret L. Biafine applied on human epidermal wounds is chemotactic for macrophages and increases the IL-1/IL-6 ratio. Skin Pharmacol. 1997; 10:281-7.
17. Biafine topical emulsion package insert. Los Angeles, CA: Ortho Dermatologics; 2009.
18. Fisher J, Scott C, Stevens R et al. Randomized phase III study comparing best supportive care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-113. Int J Radiat Oncol Biol Phys. 2000; 48:1307-10.
19. Fenig E, Brenner B, Katz A et al. Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial. Oncol Rep. 2001; 8:305-9.
20. Winter GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature. 1962; 193:293-4.
21. Hom DB, Adams G, Koreis M et al. Choosing the optimal wound dressing for irradiated soft tissue wounds. Otolaryngol Head Neck Surg. 1999; 121:591-8.
22. Chiao TB, Lee AJ. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann Pharmacother. 2005; 39:516-22.
23. Bensinger W, Schubert M, Ang KK et al. NCCN task force report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008; 6(suppl 1):S1-21.
24. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100(suppl 9):1995-2025.
25. Blanco AI, Chao C. Management of radiation-induced head and neck injury. In: Small W, Woloschak GE, eds. Radiation toxicity: a practical guide. New York: Springer; 2006:23-42.
26. Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol. 2009; 19:29-34.
27. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. WHO offset publication no. 48:16-7.
28. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100(suppl 9):2026-46.
29. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109:820-31.
30. Peterson DE, Bensadoun RJ, Rolia F. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol. 2011; 22(suppl 6):vi78-84.
31. Harris DJ, Eilers J, Harriman A et al. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs. 2008; 12:141-52.
32. Kim JH, Chu FC, Lakshmi V et al. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol. 1986; 9:132-4.
33. Epstein JB, Silverman S Jr, Paggiarino DA et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001; 92:875-85.
34. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. 1N Engl J Med. 2004; 351:2590-8.
35. Le QT, Kim HE, Schneider CJ et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011; 29:2808-14.
36. Henke M, Alfonsi M, Foa P et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2011; 29:2815-20.
37. Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract. 2005; 11:139-43.
38. Dodd MJ, Dibble SL, Miaskowski C et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90:39-47.
39. Dirix P, Nuyts S, van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer. 2006; 107:2525-34.
40. Berk LB, Shivnani AT, Small W Jr. Pathophysiology and management of radiation-induced xerostomia. J Support Oncol. 2005; 3:191-200.
41. Bhide SA, Miah AB, Harrington KJ et al. Radiation-induced xerostomia: pathophysiology, prevention and treatment. Clin Oncol (R Coll Radiol). 2009; 21:737-44.
42. Amifostine package insert. Bedford, OH: Bedford Laboratories; 2009 Jan.
43. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18:3339-45.
44. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009; 27:127-45.
45. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007; 29:58-63.
46. Pilocarpine hydrochloride package insert. Columbus, OH: Roxane Laboratories, Inc.; 2010 Nov.
47. Johnson JT, Ferretti GA, Nethery WJ et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993; 329:390-5.
48. LeVeque FG, Montgomery M, Potter D et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol. 1993; 11:1124-31.
49. Rieke JW, Hafermann MD, Johnson JT et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys. 1995; 31:661-9.
50. Evoxac (cevimeline) package insert. Edison, NJ: Daiichi Sankyo, Inc.; 2011 Nov.
51. Chambers MS, Posner M, Jones CU et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 68:1102-9.
52. Witsell DL, Stinnett S, Chambers MS. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. Head Neck. 2012; 34:1136-42.